Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
lunes, octubre 26
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Silence Therapeutics PLC
SLN
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$19.67
N/A
Últ. Act.: Oct 26, 9:30 AM
Get Report
Panorámica general
Noticias
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Comparar
Opciones
Informe de acciones
Fusiones y adquisiciones:
Silence Therapeutics (SLN) announced it will be acquired by Merck KGaA on Monday, October 19, 2026 for $1.1B paid in cash
Silence Therapeutics Financials
Silence Therapeutics (SLN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
Nasdaq Jumps Over 1% As Tech Stocks Gain: Investor Sentiment Improves, Greed Index Remains In ‘Extreme Fear’ Zone
Market sentiment improved slightly but stayed in extreme fear. Nasdaq rose 1.11%, while Silence Therapeutics surged 126% on Merck deal.
Avi Kapoor
Nasdaq Surges Over 1%; Fifth Third Bancorp Earnings Top Views
U.S. stocks mixed: Nasdaq +1.09%, S&P 500 +0.54%, Dow -0.12%. Tech led gains; utilities lagged. Oil fell, gold rose; Europe lower.
Avi Kapoor
PRO
Silence Therapeutics Q2 EPS $(0.09) Beats $(0.15) Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.09) per share which beat the analyst consensus estimate of $(0.15) by 40 percent. This is a 84.21 percent increase over losses of $(0.57) per share from
Benzinga Newsdesk
PRO
Silence Therapeutics Q1 EPS $(0.11) Beats $(0.21) Estimate, Sales $422.000K Miss $2.439M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.11) per share which beat the analyst consensus estimate of $(0.21) by 47.62 percent. This is a 45 percent increase over losses of $(0.20) per share from
Benzinga Newsdesk
Silence Therapeutics Q4 Earnings Assessment
Benzinga Insights
PRO
Silence Therapeutics Q4 EPS $(0.27) Beats $(0.43) Estimate, Sales $34.000K Miss $6.730M Estimate
Silence Therapeutics (NASDAQ:SLN) reported quarterly losses of $(0.27) per share which beat the analyst consensus estimate of $(0.43) by 37.21 percent. This is a 200 percent decrease over earnings of $0.27 per share from
Benzinga Newsdesk
